Two tripartite classification systems of CD86+ and CD206+ macrophages are significantly associated with tumor recurrence in stage II-III colorectal cancer

被引:1
|
作者
Xu, Guozeng [1 ,2 ]
Mo, Yuzhen [3 ]
Li, Jing [2 ]
Wei, Qingqing [2 ]
Zhou, Fuxiang [1 ]
Chen, Jian [4 ]
机构
[1] Wuhan Univ, Zhongnan Hosp, Dept Radiat & Med Oncol, Wuhan, Hubei, Peoples R China
[2] Guangxi Med Univ, Liuzhou Peoples Hosp, Dept Oncol, Nanning, Guangxi, Peoples R China
[3] Jinan Univ, Guangzhou Red Cross Hosp, Dept Radiat Oncol, Guangzhou, Guangdong, Peoples R China
[4] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Med Oncol, Qingdao, Shandong, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
CD86; CD206; colorectal cancer; macrophage polarization; tripartite classification system; COLON-CANCER; ADJUVANT CHEMOTHERAPY; SUPPRESSOR-CELLS; DURATION; OXALIPLATIN; EXPRESSION; PROGNOSIS; REVERSES; EVASION; SUBSET;
D O I
10.3389/fimmu.2023.1136875
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionThe prognostic value of tumor-associated macrophages remains unclear in colorectal cancer (CRC). Two tripartite classification systems, namely, ratio and quantity subgroups, were investigated as the prognostic stratification tools for stage II-III CRC. MethodsWe assessed the infiltration intensity of CD86(+) and CD206(+) macrophages in 449 cases with stage II-III disease by immunohistochemical staining. Ratio subgroups were defined by the lower- and upper-quartile points of CD206(+)/(CD86(+)+CD206(+)) macrophage ratio, including the low-, moderate-, and high-ratio subgroups. Quantity subgroups were defined by the median points of CD86(+) and CD206(+) macrophages and included the low-, moderate-, and high-risk subgroups. The main analysis was recurrence-free survival (RFS) and overall survival (OS). ResultsRatio subgroups (RFS/OS: HR=2.677/2.708, all p<0.001) and quantity subgroups (RFS/OS: HR=3.137/3.250, all p<0.001) could serve as independent prognostic indicators that effectively predicted survival outcomes. More importantly, log-rank test revealed that patients in the high-ratio (RFS/OS: HR=2.950/3.151, all p<0.001) or high-risk (RFS/OS: HR=3.453/3.711, all p<0.001) subgroup exhibited decreased survival outcomes after adjuvant chemotherapy. The predictive accuracy of the quantity subgroups within 48 months was higher than that of the ratio subgroups and tumor stage (all p<0.05). ConclusionsRatio and quantity subgroups could serve as independent prognostic indicators that could potentially be incorporated into the tumor staging algorithm to improve prognostic stratification and provide better predictions of survival outcomes in stage II-III CRC after adjuvant chemotherapy.
引用
收藏
页数:11
相关论文
共 15 条
  • [1] The Ratio of CD86+/CD163+Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer
    Xu, Guozeng
    Jiang, Lei
    Ye, Cheng
    Qin, Guizhen
    Luo, Zhanxiong
    Mo, Yuzhen
    Chen, Jian
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] CD86+/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma
    Sun, Dalong
    Luo, Tiancheng
    Dong, Pingping
    Zhang, Ningping
    Chen, Jing
    Zhang, Shuncai
    Liu, Longzi
    Dong, Ling
    Zhang, Si
    PEERJ, 2020, 8
  • [3] CD86+/CD206+, Diametrically Polarized Tumor-Associated Macrophages, Predict Hepatocellular Carcinoma Patient Prognosis
    Dong, Pingping
    Ma, Lijie
    Liu, Longzi
    Zhao, Guangxi
    Zhang, Si
    Dong, Ling
    Xue, Ruyi
    Chen, She
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (03):
  • [4] Tumor-associated macrophages and risk of recurrence in stage III colorectal cancer
    Cavalleri, Tommaso
    Greco, Luana
    Rubbino, Federica
    Hamada, Tsuyoshi
    Quaranta, Maria
    Grizzi, Fabio
    Sauta, Elisabetta
    Craviotto, Vincenzo
    Bossi, Paola
    Vetrano, Stefania
    Rimassa, Lorenza
    Torri, Valter
    Bellazzi, Riccardo
    Mantovani, Alberto
    Ogino, Shuji
    Malesci, Alberto
    Laghi, Luigi
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2022, 8 (04) : 307 - 312
  • [5] Tumor aggression-defense index-a novel indicator to predicts recurrence and survival in stage II-III colorectal cancer
    Wu, Tong
    Fang, Lin
    Ruan, Yuli
    Shi, Mengde
    Su, Dan
    Ma, Yue
    Ma, Ming
    Wang, Bojun
    Liao, Yuanyu
    Han, Shuling
    Lu, Xiaolin
    Zhang, Chunhui
    Liu, Chao
    Zhang, Yanqiao
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [6] High Infiltration of CD203c+Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer
    Li, Jing
    Mo, Yuzhen
    Wei, Qingqing
    Chen, Jian
    Xu, Guozeng
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 723 - 735
  • [7] A Prediction Model for Tumor Recurrence in Stage II-III Colorectal Cancer Patients: From a Machine Learning Model to Genomic Profiling
    Chen, Po-Chuan
    Yeh, Yu-Min
    Lin, Bo-Wen
    Chan, Ren-Hao
    Su, Pei-Fang
    Liu, Yi-Chia
    Lee, Chung-Ta
    Chen, Shang-Hung
    Lin, Peng-Chan
    BIOMEDICINES, 2022, 10 (02)
  • [8] Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer
    Chaput, N.
    Svrcek, M.
    Auperin, A.
    Locher, C.
    Drusch, F.
    Malka, D.
    Taieb, J.
    Goere, D.
    Ducreux, M.
    Boige, V.
    BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 1013 - 1022
  • [9] Infiltration of CD204-overexpressing Macrophages Contributes to the Progression of Stage II and III Colorectal Cancer
    Tada, Yoichiro
    Matsumi, Yoshiaki
    Hara, Kazushi
    Miyauchi, Wataru
    Sugesawa, Ken
    Uejima, Chihiro
    Tanio, Akimitsu
    Kihara, Kyoichi
    Yamamoto, Manabu
    Takano, Shuichi
    Sakamoto, Teruhisa
    Nakayama, Yuji
    Hasegawa, Toshimichi
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2021, 41 (10) : 4857 - 4865
  • [10] Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients
    Zhang, Nian-Hua
    Li, Jie
    Li, Yin
    Zhang, Xin-Tao
    Liao, Wen-Ting
    Zhang, Jun-Yi
    Li, Rung
    Luo, Rong-Cheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (06) : 973 - 982